4D: die deutsche diabetes dialyse studie

principal researchers

Vera Krane (University of Wurzburg)

Christoph Wanner (University of Wurzburg)

data custodian

University of Wurzburg

funding

Pfizer Inc. (original study)

University of Wurzburg (current work)

key publications

• Design paper: Kidney Int Suppl 1999; 56 (Suppl.71): S-222–S-226

• Baseline characteristics: Kidney Blood Press Res 2004; 27(4): 259-66

• Main results: N Engl J Med 2005; 353: 238-48

• Change in N-terminal-pro-B-type-natriuretic-peptide: Eur Heart J 2008; 29: 2092-9.

• Inflammation and outcome: Kidney Int 2008; 74: 1461-7

• Inflammation LDL-C and outcome: Am J Kidney Dis 2009; 54: 902-11

• Glycemic control: Circulation 2009; 120: 2421-8

• Apolipoprotin E and genotype: Atherosclerosis 2010; 208: 197-202

• Diabetes: Clin J Am Soc Nephrol 2010; 5(5): 856-66

• Patients on haemodialysis: Clin J Am Soc Nephrol 2011; 6: 1316-25

• Kinesin-like protein-6 Trp719Arg polymorphism: Atherosclerosis 2011; 219: 659-62

• Apolipoprotein A-IV concentrations and outcome: J Intern Med 2012; 272: 592-600

• Predicting erythropoietin resistance: BMC Nephrol 2013; 14: 67

• Aldosterone and cortisol: Eur Heart 2013; 34: 578-87

• Pregnancy-associated plasma protein: Atherosclerosis 2014; 236: 263-9

• 10 year follow-up: Clin Exp Nephrol 2014; 18(2): 274-7

• Erythropoietin-stimulating agent responsiveness and outcome: Nephron Clin Pract 2014; 128: 147-52

• HDL Proteins and outcomes: Clin J Am Soc Nephrol 2015; 10: 224-31

• Intestinal cholesterol absorption: J Am Coll Cardiol 2015; 65: 2291-8

• Protein carbamylation and outcome: Kidney Int 2015; 87: 1201-8

• 10 year follow-up: Kidney Int 2016; 89: 1380-1387